ReviewRadiology and oncology2019
The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
Review in Radiology and oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.Current treatment options in oncology · 2026Review
- Pancreatic neuroendocrine tumors: A case-based evidence review.World journal of gastrointestinal pathophysiology · 2025Review
- Navigating care: understanding cancer patients' experiences with systemic radionuclide therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics.Journal of clinical medicine · 2024Review
- Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessment.La Radiologia medica · 2023Article
- Radiomics and artificial intelligence analysis by T2-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging to predict Breast Cancer Histological Outcome.La Radiologia medica · 2023Article
- Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and Limits of Radiomics.Diagnostics (Basel, Switzerland) · 2023Review
- Pancreatic cancer detection with a non-contrast MR protocol: is it reliable?La Radiologia medica · 2023Article
- Colorectal liver metastases patients prognostic assessment: prospects and limits of radiomics and radiogenomics.Infectious agents and cancer · 2023Review
- Dose Reduction Strategies for Pregnant Women in Emergency Settings.Journal of clinical medicine · 2023Review
- Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments.Journal of clinical medicine · 2023Review
- Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence.Biology · 2023Review
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- Imaging Features of Main Hepatic Resections: The Radiologist Challenging.Journal of personalized medicine · 2023Review
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.Cancers · 2023Review
- Fortuitous discovery of an early neuroendocrine tumor during appendicular peritonitis.Annals of medicine and surgery (2012) · 2022Article
- Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams.Journal of personalized medicine · 2022Review
- Imaging Features of Post Main Hepatectomy Complications: The Radiologist Challenging.Diagnostics (Basel, Switzerland) · 2022Review
- Complications Risk Assessment and Imaging Findings of Thermal Ablation Treatment in Liver Cancers: What the Radiologist Should Expect.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are a heterogeneous group of tumours. An effective diagnosis requires a multimodal approach that combines evaluation of clinical symptoms, hormonelevels, radiological and nuclear imaging, and histological confirmation. Imaging plays a critical role in NETs diagnosis, prognosis and management, so the radiologists are important members of the multidisciplinary team. During diagnostic work-up two critical issues are present: firstly the need to identify tumor presence and secondly to define the primary site and assess regional and distant metastases. Conclusions The most appropriate imaging technique depends on the type of neuroendocrine tumour and the availability of specialized imaging techniques and expertise. There is no general consensus on the most efficient imaging pathway, reflecting the challenge in reliably detection of these tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.